Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study.

Luigi GargiuloLuciano IbbaMatteo BiancoSara Di GiulioAlfano AlfanoRuggero Cascio IngurgioPaola FacherisChiara PeruginiMario ValentiAntonio CostanzoAlessandra Narcisi

Published in: The Journal of dermatological treatment (2024)

Keyphrases

atopic dermatitis
early onset
high intensity
randomized controlled trial
drug induced
placebo controlled